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’ INTRODUCTION
Histamine receptors (HRs) are aminergic G protein-coupled
receptors (GPCRs) with seven transmembrane (TM)-spanning
helices serving as a mediator in hypersensitivity (allergic) re-
sponses, gastric acid secretion, neurotransmission, immune-
modulation, cell differentiation, and embryonic development,
among others.3 Four subtypes of human HRs, H1, H2, H3, and
H4, have been identified.
4 All HRs are excellent drug targets for
the treatment of such diseases as schizophrenia, Alzheimer’s
disease (AD), dementia, anxiety, tremor (Parkinson’s disease),
attention deficit hyperactivity disorder (ADHD), mood disor-
ders, sleep disorders (narcolepsy), depression, migraine, aller-
gies, asthma, ulcers, stroke, epilepsy, obesity, diabetes, and
cancer.5 Indeed human histamine H1 receptor (hH1HR) antago-
nists (antihistamine) are widely used in the treatment of allergy.6
In addition, hH2HR antagonists are used in treating peptic
ulcers, gastresophageal reflux disease, and gastrointestinal bleed-
ing.7,8 The hH3HR antagonists have been proposed for such
therapeutic applications as treatment of Alzheimer’s disease,
attention deficit hyperactivity disorder (ADHD), epilepsy, and
obesity.1 The hH4HR has been suggested as an interesting drug
target for the therapy of inflammation, allergy, and autoimmune
disorders.9
While hH1HR, hH2HR, and hH4HRs have been successful
targets of blockbuster drugs for treating allergic diseases, gastric
ulcer, and chronic constipation, the development of hH3HR
ligands still lags on their way to market, at least partly because of
problemswith selectivity. Thus, we decided to focus on developing
an understanding of how to make ligands selective for hH3HR.
The Results and Discussion Section describes the prediction
of 3D structures for all four subtypes (H1, H2, H3, and H4) of
hHRs, using the GEnSeMBLE (GPCR ensemble of structures in
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ABSTRACT:Histamine receptors (HRs) are excellent drug targets for the treatment
of diseases, such as schizophrenia, psychosis, depression, migraine, allergies, asthma,
ulcers, and hypertension. Among them, the human H3 histamine receptor (hH3HR)
antagonists have been proposed for specific therapeutic applications, including
treatment of Alzheimer’s disease, attention deficit hyperactivity disorder (ADHD),
epilepsy, and obesity.1 However, many of these drug candidates cause undesired side
effects through the cross-reactivity with other histamine receptor subtypes. In order to
develop improved selectivity and activity for such treatments, it would be useful to
have the three-dimensional structures for all four HRs. We report here the predicted
structures of four HR subtypes (H1, H2, H3, and H4) using the GEnSeMBLE (GPCR
ensemble of structures in membrane bilayer environment) Monte Carlo protocol,2
sampling ∼35 million combinations of helix packings to predict the 10 most stable
packings for each of the four subtypes. Then we used these 10 best protein structures
with the DarwinDockMonte Carlo protocol to sample∼50 000 1020 poses to predict the optimum ligandprotein structures for
various agonists and antagonists. We find that E2065.46 contributes most in binding H3 selective agonists (5, 6, 7) in agreement with
experimental mutation studies. We also find that conserved E5.46/S5.43 in both of hH3HR and hH4HR are involved in H3/ H4
subtype selectivity. In addition, we find that M3786.55 in hH3HR provides additional hydrophobic interactions different from
hH4HR (the corresponding amino acid of T323
6.55 in hH4HR) to provide additional subtype bias. From these studies, we developed
a pharmacophore model based on our predictions for known hH3HR selective antagonists in clinical study [ABT-239 1, GSK-
189,254 2, PF-3654746 3, and BF2.649 (tiprolisant) 4] that suggests critical selectivity directing elements are: the basic proton
interacting with D1143.32, the spacer, the aromatic ring substituted with the hydrophilic or lipophilic groups interacting with
lipophilic pockets in transmembranes (TMs) 356 and the aliphatic ring located in TMs 237. These 3D structures for
all four HRs should help guide the rational design of novel drugs for the subtype selective antagonists and agonists with reduced
side effects.
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membrane bilayer environment) method2 for generating the
ensemble of the 10 most stable 3D structures of these GPCRs.
Then Methods Section reports the predictions from the
DarwinDock method of the binding sites for structurally known
antagonists 1, 2, 3, 4 now in clinical studies, three agonists (5, 6, 7),
five antagonists (clobenpropit 8 N0-[(4-chlorophenyl)methyl]-
1-[3-(3H-imidazol-4-yl)propylsulfanyl]formamidine, ciproxifan 9,
thioperamide 10, A-304121 [4-(3-((2R)-2-aminopropanoyl-
1-piperazinyl)propoxy)phenyl)cyclopropylmethanone] 11, and
A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)-
propyl)-1-piperazinyl)-1-methyl-2-oxo-ethyl-)-2-furamide] 12 for
the structureactivity relationship (SAR) studies.10
The Methods Section extends the comparison of the 3D
structure of our predicted structure with the recently reported
3.1 Å crystal structure of the hH1HRT4-lysozyme fusion
protein (H1RT4L) complex with doxepin.11 Since we pre-
dicted the 3D structure of all HRs when no X-ray structure of the
HRs was available, this comparison will validate our methods.
The 1.3 Å root mean squared deviation (RMSD) in TM between
two structures reveals our atomic details of binding site, and the
model will be highly useful for guiding rational design of ligands
with high H3HR selectivity.
’RESULTS AND DISCUSSION
GEnSeMBLE Predictions of Apoprotein Structures for
All Four HRs. The seven TM domains of four hHRs in Figure 1
were predicted by PredicTM which combines hydrophobicity
analysis and multiple sequence alignment of sequences using the
MAFFT12 program. Hydrophobic profile in the multiple se-
quence alignment, using the thermodynamic and biological
hydrophobic scales from White and von Heijne,13,14 shows all
hHRs have seven TM characters as shown in GPCRs; hH2HR
has a shorter intracellular three loop compared to other subtypes.
Figure 2 shows the final TM regions and multiple alignments of
all HRs from PredicTM. All TM regions of 4 subtypes applied by
capping rules are in good agreement within 15 residue
difference at the terminal end.
The GEnSeMBLE method2 was used to predict the 3D
structure of all 4 HRs before the X-ray structure of the H1HR
was reported.11 In GEnSeMBLE we start with some template
structures and consider 12 rotations (30 pitch) about the helix
axis for each of the 7 TM regions, leading to (7)12 ∼35 million
packings. We then estimate the energy for all 35 million based on
the pairwise interactions of the 12 strongly interacting pairs. In
these calculations we start with several experimental and com-
putational templates and finally select those with the best total
interaction energies.
However when we started this project X-ray crystal structures
were avaible for the human β2 adrenergic receptor (PDB: 2RH1)
15
and the turkey β1 adrenergic receptor (PDB: 2VT4).
16 Con-
sequently we deviated from our standard methodology for pre-
dicting histamine receptor structures as follows:
First, the TM regions in the two templates were identified and
the corresponding regions in the four histamine receptors identi-
fied based on the higher sequence homology in the TM regions
(Table S1, Supporting Information). Overviews over which
residues are part of the TM region for each of the four HRs
are shown in Table S2, Supporting Information.
Then, each TM was mutated to match the HR of interest and
energy-minimized in vacuous. Then the 7 helix bundle was used
as input to the BiHelix protocol of GEnSeMBLE2 in which 144
combinations are considered for each pair each with reoptimized
side chains. Here, each of the seven TMs was rotated system-
atically(90 using a 15 sampling interval, leading to structures
for the packed bundle. Then we superimposed the BiHelix
energies to estimate the 1000 energetically most favored 7 TM
helix bundles. These bundles were then built, the side-chains
reoptimized, using the SCREAM procedure,17 and the total
energies were calculated using both the standard charged model
(where Asp, Glu, Lys, Arg have net charges) and the neutral
model we have developed.18 From these 1000 we collected the
Figure 1. Hydropathy prediction from PredicTM for the four HRs.
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best 10 in Table 1 for each combination of HR and template.
These results make it clear that for hH1HR and hH3HR the
structures derived from the human β2 adrenergic receptor were
significantly more favorable energetically than models derived
from the turkey β1 adrenergic receptor. In contrast, for hH2HR
and hH4HR the structures derived from the turkey β1 adrenergic
receptor were most favorable.
For these best 10 structures, we examine new configurations
including rotations of(15 for TM3, 15,(30, 45 for TM4,
and 15 for TM5. We found that the structure derived directly
from the initial helix bundle (i.e., with η = 0 for all 7 helices) was
not unreasonably high in energy. This preference for structures
near 0 supports the applicability of these two X-ray crystal
structures as a reasonable starting point for the BiHelix sampling.
Indeed, the top-scoring structures for all four HRs differed in the
rotation of only a single one of the seven TMs. For hH3HR, the
top-scoring model had a 30 rotation of TM4 (human β2
adrenergic receptor as template), whereas for hH1HR the top-
scoringmodel had a +15 rotation of TM4 (human β2 adrenergic
receptor as template). Moreover for hH2HR the top-scoring
model had a 15 rotation of TM4 (turkey β1 adrenergic
receptor as template), while for hH4HR the top-scoring model
had a +15 rotation of TM5 (turkey β1 adrenergic receptor as
template).
Compared with hH1HR (20.90% in overall, 32.15% in TM)
and hH2HR (17.30% in overall, 33.08 in TM) with low sequence
identity in Table S1 in Supporting Information, hH4HR has a
sequence identity of 34.83% to hH3HR and 54.84% in TM
regions. Many compounds with reported affinity for hH3HR also
have affinity for hH4HR. Compounds like clozapine and cloben-
propit behave as partial agonists at hH4HR and as antagonists
at hH3HR, showing some functional selectivity.
19 Many drug
candidates cause undesired side effects through their cross-
reactivity. To develop improved selectivity and activity for such
treatments, we use the 10 most stable three-dimensional struc-
tures for all four HRs.
Predicted Structures for Ligands Binding to All Four HRs.
First generation hH3HR antagonists were monoalkyl-substituted
imidazole-based derivatives like thioperamide, clobenpropit, or
ciproxifan.20 Potent stimulation of hH3HR has been observed by
imidazole derivatives only. Claimed interaction potential to
cytochrome P450 (CYP) isozymes caused by the imidazole
moiety related to elements of the porphyrine cycle and some-
times complex pharmacological behavior led to imidazole
Figure 2. Alignments of the four HR subtypes, H1, H2, H3, and H4 from the PredicTM method. The predicted TM regions from PredicTM are
displayed in colored boxes (TM1 in purple, TM2 in blue, TM3 in cyan, TM4 in green, TM5 in yellow, TM6 in orange, TM7 in red). Highly conserved
residues in family A GPCRs are shown in red in TM16 and white in TM7. Variable amino acids among the four subtypes in the upper TM regions are
marked with red asterisks, and subtype selective residues predicted from the cavity analysis are boxed. We use BallesterosWeinstein numbering
consisting of the TM helix number followed by residue number relative to the highly conserved residue in the helix, numbered as 50. H-bonding is
indicated by arrows, and subtype selective residues are shown in red.
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replacements. A general pharmacophore element of these nonim-
idazole derivatives has been described which is nowadays shown
in numerous variations and combinations: A basic moiety is linked
by a spacer to a central, mostly aromatic core structure which then is
connected to further affinity enhancing elements, e.g., another basic
moiety or hydrophilic/lipophilic groups or a combination thereof.21
Chart 1. Chemical Structures of Structurally Known Histamine H3 Receptor Antagonists in Clinical Study, ABT-239 1,
GSK-189254A 2, PF-3654746 3, and BF2.649 (Tiprolisant) 4a
aBinding affinities (pKi) are shown for H3 with its function in parentheses compared to the endogenous histamine.
Table 1. Top 10 Predicted Structures of the 4 hHRs from the CombiHelix Analysis of the (13)7 = 62 748 517 BiHelix
Packing Geometries Within (90 Angle Range by 15 Incrementsa
aAll 1000models fromCombiHelix were selected for neutralization by their charge total energy (E) score (ChargeTot: kcal/mol). The final 100models
were ordered by neutral total E (NeutTot: kcal/mol). The case with η = 0 for all 7 helices is represented in italic, and the best E is shown in bold. CIH is
charge interhelical energy, CTot is charge total energy, NIH is neutral interhelical energy, and NTot is neutral total energy. *The case with η = 0 for all
7 helices is ranked as 12 (E: 43.6 kcal/mol) in hH3HR-β2 and 34 in hH4HR-β1 (E: 298.9 kcal/mol), respectively.
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A number of hH3HR antagonists have advanced to the clinical
area for the potential treatment of human cognitive disorders.22
These include 4-(2-{2-[(2R)-2-methylpyrrolidin-1-yl]ethyl}-
benzofuran-5-yl)benzonitrile, (ABT-239 1), 6-[(3-cyclobutyl-
2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyr-
idinecarboxamide hydrochloride (GSK189254 2), (1R,3R)-N-
ethyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)phenyl]
cyclobutane-1-carboxamide (PF-03654746 3), 1-{3-[3-(4-
chlorophenyl)propoxy]propyl} piperidine hydrochloride
(BF2.649 4), MK-0249 (structure not yet disclosed), JNJ-
17216498 (structure not yet disclosed), and ABT-288 (structure
not yet disclosed).
Among these, we selected structurally known compounds
(structures shown in Chart 1) like ABT-239 1 (pKi: 9.35 at
hH3HR), for cognitive disorder (Phase I),
23 GSK-189254A 2
(pKi: 9.59 at hH3HR) for dementia, narcolepsy, and schizophrenia
(Phase I),24 PF-3654746 3 (pKi: 8.49 at hH3HR) for allergic
rhinitis (Phase II), and BF2.649 4 (tiprolisant, pKi: 8.3 at hH3HR)
for central nervous system disease: hypersommina and narcolepsy
(Phase II)25 for docking studies.
As summarized in the Methods Section, the DarwinDock
method for predicting ligand binding sites starts by sampling
the full protein to locate putative binding regions and then
aims at sampling a complete set of ligand conformation (∼20)
for each; of which we sample a complete set of poses (∼50 000)
from which we select the best poses using the total binding
energy, E.
Endogenous Agonist Histamine. We docked histamine, the
endogenous agonist 5, to the lowest E predicted structure of
hH3HR in Table 1 from CombiHelix.
Most of poses show salt bridges at D1143.32 or E2065.46 with
the protonated nitrogen atom or one of the nitrogen atoms in
the imidazole ring. Our cavity analysis (Table 2) of the histamine
bound to hH3HR shows that the major contributing amino acids
in ligand binding are E2065.46 (5.08 kcal/mol), F2075.47
(3.81 kcal/mol), Y1153.33 (3.09 kcal/mol), and D1143.32
(2.12 kcal/mol) based on nonbonding energies (defined in
the Methods Section as the sum of vdW, electrostatic Coulomb
with 2.5 dielectric constant, and H-bond energies). This result
agrees with previous docking studies which shows all hydro-
philic interactions at D1143.32/E2065.46 and hydrophobic inter-
actions at Y1153.33, Y3746.51, and F3987.39, as found in bovine
rhodopsin-based hH3HR homology models.
26 Histamine has
similar interactions in hH4HR with the main interaction at
D1143.32/E2065.46.27,28 Supporting this, the Ala mutation of
E2065.46, which was the most major contributing residue in the
cavity analysis (Table 2), shows dramatic loss of agonist with
more than 2000-fold decrease. In addition, T204A5.44 and
A202Q5.42 mutants display substantial decrease of histamine
binding with 5.7- and 4.2-fold decrease compared with the wild-
type, respectively.26
In the neutral system of histamine-hH3HR, we find that the
deprotonated nitrogen atom of the histamine interacts with the
protonated D1143.32, while the protonated E2065.46 also
H-bonds with the ε-NH atom in the imidazole ring of histamine,
as shown in Figure 3. An additional hydrophobic interaction
occurs at F2075.47 and Y1153.33.
hH3HR Selective Agonists 5, 6, 7. We next matched the H3
selective agonist, (R)-α-methyl histamine 6, to validate the
binding site of histamine at hH3HR, leading to common
interactions at E2065.46 (4.73 kcal/mol), F2075.47 (3.99
kcal/mol), D1143.32 (2.96 kcal/mol), and Y1153.33 (2.38
kcal/mol). However, the stereoisomer, (S)-α-methyl hista-
mine 7, with ∼100-fold less binding affinity reveals unfavor-
able interactions at Y1153.33 (+6.84 kcal/mol) because of the
bad contact with the α-methyl group (Table 3 and Figure 4).
The result is a dramatic decrease in binding affinity (cavity
sum =18.07 for (R)-α-methyl histamine 6 vs8.39 for (S)-
α-methyl histamine 7) in agreement with the dramatically
decreased experimental binding affinity of (S)-α-methyl
Figure 3. Predicted best models of the endogenous agonist histamine 5
bound to hH3HR. The H-bonding is represented by the arrows with the
distance between the donor and the acceptor. The number with residue
is from the order of unified cavity E in Table 2. Schematic structure of the
predicted binding sites is displayed in the bottom figure.
Table 2. Cavity Energy of the Endogenous Agonist Hista-
mine Bound to theHumanHistamineH3 Receptor (hH3HR)
a
aResidues are ordered by total NonBond energy, which is the sum of van
der Waals (vdW), Coulomb, and H-bond energy (kcal/mol) in the
unified cavity. The color coding for contributions of each residue to
binding of the adenosine ligand is: dark grey: > 3 kcal/mol, grey: 1 - 3
kcal/mol, light grey: 0.5 - 1.0 kcal/mol. The experimental point-
mutation result was compared.
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histamine 7 at hH3HR (pKi at hH3HR: 8.2 for 6 vs 7.2
for 7).29
The cavity analysis of the H3 selective agonists (5, 6, 7) suggests
the major contributing amino acid is E2065.46 (Tables 2 and 3).
These docking results are in good agreement with the current
mutational study. Themost pronounced reduction in potency and
affinity of the agonists was seen with the mutation of E2065.46.26
Thus the stereoselectivity of the methylated histamine deriv-
atives is explained by these docking studies. The result agrees
with experimental observations that the methylated histamine
derivative, (R)-α-methylhistamine, is the more selective and the
potent hH3HR agonist. The (S)-stereoisomer is about 100 times
less potent than the (R)-isomer.29
Docking of hH3HR Selective Antagonist 8, Clobenpropit, at
All Four HRs and Further SAR Studies. Antagonist docking
started from the assumption that classical H3 antagonists, such
as monoalkyl-substituted imidazole-based derivatives, would share
the interaction between their imidazole ring and E2065.46, as
shown in the endogenous agonist, histamine 5. This hypothesis is
based on the partial structural similarity between histamine and
imidazole-containing H3 antagonists (i.e., the imidazole ring, the
spacer, and the basic or polar portion).
We docked hH3HR selective antagonist 8, clobenpropit, to the
lowest E predicted structures of all four hHRs of Table 1. From
the cavity analysis of H3 subtype selective clobenpropit 8 bound
to hH3HR, Table 4 shows that the major contributing amino
acids are Y1153.33 (4.96 kcal/mol), W4027.43 (4.71 kcal/
mol), and D1143.32 (3.73 kcal/mol). The major H-bonding is
shown at D1143.32 and Y3746.51 with the isothiourea group.
Additional H-bonding with the terminal imidazole ring is formed
at E2065.46. The para-chloro-benzyl group of clobenpropit 8 is
surrounded by hydrophobic residues, L4017.42 and W4027.43, as
shown in Figure 5.
Table 3. Cavity Energy of the H3 Selective Agonist (R)-α-Methyl Histamine vs (S)-α-Methyl Histamine at hH3HR
a
aResidues are ordered by total NonBond energy of (R)-methyl histamine, which is the sum of vdW, Coulomb, and H-bond energy (kcal/mol) in the
unified cavity. (S)-α-methyl histamine with ∼100-fold less binding affinity29 displayed unfavorable interaction at Y115 with α-methyl groups in italic
font. The color coding for contributions of each residue to binding of the adenosine ligand is: dark grey: > 3 kcal/mol, grey: 13 kcal/mol, light grey:
0.51.0 kcal/mol.
Figure 4. Superposition of the H3 selective agonist (R)-α-methyl
histamine 6 and (S)-α-methyl histamine 7 to the hH3HR. The H-bond-
ing is represented by the arrows between the donor and the acceptor.
(S)-α-methyl histamine with ∼100-fold less binding affinity displayed
unfavorable interaction at Y115 with α-methyl groups in red arrow. The
number with residue is from the order of unified cavity E in Table 3.
Schematic structure of the predicted binding sites is displayed in the
bottom figure.
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To understand subtype selectivity, we matched the predicted
best binding pose of the highly H3-selective ligand clobenpropit 8
at hH3HR to other three subtypes (H1, H2, H4) of hHRs, and
then we used SCREAM17 to predict the optimum side chain
position of residues in the binding pocket, after which we
minimized the final ligand/protein complex post neutralization.
Predicted subtype residues that vary among four subtypes (H4:
29%, 8/28, H1: 57%, 16/28, H2: 68%, 19/28) are displayed in
Table 4. The corresponding amino acids of conserved E5.46/
S5.43 in both of hH3HR and hH4HR are N198
5.46/ A1955.43 in
hH1HR and T190
5.46/ G1875.43 (Figure 2). Both of two subtype
variable residues in hH1HR and hH2HR show weakened inter-
actions in the cavity in Table 4 and Figure 6, resulting in a
2.22.4 kcal/mol favorable interaction in hH3HR. However, the
similar interaction is shown at these two conserved residues of
hH4HR. Thus, the final cavity sum is a substantial decrease in
binding affinity (cavity sum = 34.11 in hH1HR, 33.77 in
hH2HR) in agreement with the dramatically decreased experimental
binding affinity at hH1HR (pKi: 5.6) and hH2HR (pKi: 5.2).
The final cavity sum with the weakened binding affinity at
hH4HR (pKi: 7.4) is a 35.12 kcal/mol compared with the
cavity sum of hH3HR (pKi: 9.4), 36.94 kcal/mol. Thus, this
predicted binding energy is consistent with the experimental
binding affinity of H3 subtype selective clobenpropit 8.
30 The
predicted structures were ordered by experimental binding
affinity, including unified cavity energy (UniCav E) in Table 5
in all subtypes of hHRs. Furthermore, all scoring energies at
all HRs parallel with theirs experimental binding affinities
with the r2 values (correlation coefficients) of 0.67 to 0.99
(Figure 7).
For further SAR studies, we included four more antagonists,
ciproxifan 9, thioperamide 10, A-304121 11, and A-317920 12 in
the same literature.30 Predicted binding cavity energies for eight
models in good agreement with experimental relative binding
constants (r2 = 0.65 for all 8 and r2 = 0.93 for 6 excluding the
flexible ligands, A-304121 11, and A-317920 12, which include
more than 10 rotatable bonds in their structures in Figure 7). All
of them share the same binding site with major anchoring site at
D1143.32 in Figure 6.
Based on the docking studies of the subtype selective
antagonist clobenpropit 8, we suggest that E5.46/S5.43 in
hH3HR and hH4HR are involved in additional H-bonding
Table 4. Cavity Energy of the H3 Selective Antagonist Clobenpropit 8 to Four Human HRs
a
aResidues are ordered by total NonBond energy (H3), which is the sum of vdW, Coulomb, and H-bond energy (kcal/mol) in the unified cavity.
Predicted subtype residues that vary among four subtypes (H4: 29%, 8/28, H1: 57%, 16/28, H2: 68%, 19/28) are displayed in italic font. The color
coding for contributions of each residue to binding of the adenosine ligand is: dark grey: > 3 kcal/mol, grey: 1 - 3 kcal/mol, light grey: 0.5 - 1.0 kcal/mol.
In the BallesterosWeinstein numbering, the most conserved residue in each of the seven TM domains is taken as the reference and numbered as 50.
This residue is designated x.50 where x is the number of the TM helix.
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interactions with the terminal imidazole group in the mono-
alkyl-substituted imidazole-based derivatives, however these
interactions are lost in hH1HR and hH2HR, as shown in
Figure 6. Supporting this, sequence alignments show that
TM5 of the hHRs is poorly conserved, suggesting a potential
differences in the mechanism in which histamine binds to the
hH3HR. For the difference between hH3HR and hH4HR,
M3786.55 in hH3HR (which is the corresponding amino acid
of T3236.55 in hH4HR) stabilizes through additional hydro-
phobic interactions (1.28 kcal/mol at M3786.55 vs 0.41
kcal/mol at T3236.55). Thus this predicted structure explains
the increase of H3 selectivity for clobenpropit 8 at hH3HR over
the other three subtypes.
In addition, scoring energy of hH3HR selective antagonist
clobenpropit for all HRs correlates with the observed experi-
mental binding affinities with r2 values (correlation coefficients)
of 0.690.98.
Docking of Structurally Known hH3HR Selective Antagonists
in Clinical Studies. Docking studies were also carried out using
structurally known hH3HR selective antagonists in clinical trials,
ABT-239 1, GSK-189,254 2, PF-3654746 3, and BF2.649 4. To
develop a general pharmacophore model for these nonimidazole
derivatives with hH3HR selectivity, we selected structurally
known hH3HR targeting drugs in phase I or II preclinical studies,
ABT-239 1 (pKi: 9.35), GSK-189254A 2 (pKi: 9.59), PF-
3654746 3 (pKi: 8.49), and BF2.649 4 (tiprolisant, pKi:
8.3) for further docking studies.
As shown in Figure 8, the binding sites of four antagonists
overlap, as expected. A central basic moiety shows common
H-bonding at D1143.32. An aromatic core structure leads to
further affinity enhancing elements, e.g., hydrophilic/lipophilic
groups are surrounded by hydrophobic cavity in TMs 356
region. The aliphatic ring including a protonated nitrogen is
surrounded by another hydrophobic cavity in TMs 237.
GSK-189254A 2 shows an extra H-bond at S2035.43 with the
nitrogen atom in the pyridine ring. PF-3654746 3 also forms
additional H-bonding interactions among the terminal amino
group, Y1945.34 and E2065.46, and between F substituent and
Y3746.51.
All hH3HR selective antagonists could be mutually super-
posed following a common pharmacophore model with similar
arrangements at the same binding site. The proposed pharma-
cophore model suggests the basic proton interacting with
D1143.32, the spacer, the aromatic ring substituted with the
hydrophilic or lipophilic groups interacting with lipophilic pock-
ets in TMs 356 and the aliphatic ring located in TMs 237.
This model is in good agreement with the current generally
accepted model; a basic amine motif separated by several atoms
from the central, typically hydrophobic, core, which is joined on
the other side by a structurally variable region in the form of
another basic amine or a polar, nonbasic arrangement (e.g.,
amide).5
Structure Comparison of Predicted Structure and the
Experimental X-ray Structure of the hH1HR (PDB ID: 3RZE).
11 Compared to the crystal structure of the hH1HR, the RMSD
of the predicted hH1HR structure generated by our GEnSeM-
BLE method showed 1.33 Å RMSD in whole TMs, as shown in
Table 6. There were also no big differences with other subtypes
in the average backbone RMSD of TM helices with less than
1.64 Å for all three hH2HR (1.64 Å), hH3HR (1.33 Å), and
hH4HR (1.60 Å). The most similar structure of hH1HR is
hH3HR with 0.04 Å. Among TMs major structural deviations
are shown at the TMs 1 and 5 with 0.85 and 0.84 Å RMSD,
respectively.
The recent availability of GPCR crystal structures provides
some mechanistic insights into both the inactive and active
forms, which should be useful in designing ligands for therapeutic
applications. These results show that the seven-helix TM topol-
ogy of these receptors can exhibit multiple conformations with
variations in interhelical orientations, which in turn can change
the binding site and energy of various ligands. These multiple
conformations are observed both for a given GPCR in different
functional forms (e.g., inactive vs active) and across different
GPCRs. The conformational variations already found in the
crystallized GPCRs strongly suggest that homology models
based on a single template would not be sufficiently flexible to
Table 5. Calculated Binding Energies (E, kcal/mol) of the H3
Selective Antagonist Clobenpropit 8 Bound to Four Human
HR and Other Antagonists (Ciproxifan 9, Thioperamide 10,
A-304121 11, A-317920 12 at hH3HR
a
a Energetically favorable E is in grey shading. LocalCav: local cavity E,
UnifiedCav: unified cavity E, Snapbe: snap binding E = complex E 
(protein E ligand E), SnapbeSol: snap binding E including solvation E
with Delphi method
Figure 5. Predicted best models of the H3 selective antagonist
clobenpropit 8 bound to the hH3HR. The H-bonding is represented
by the arrows between the donor and the acceptor. The number with
residue is from the order of unified cavity E in Table 5. Schematic
structure of the predicted binding sites is displayed in the bottom
figure.
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describe the multiple functional forms of a receptor and would be
unlikely to predict the important configurations of other GPCRs.
The GEnSeMBLE method applied in this paper was devel-
oped to enable exhaustive sampling of the conformational space
to sample the variety of packings explored by receptors. We
expect that this procedure dramatically increases the likelihood of
predicting accurate structures for functionally distinct conforma-
tions of a GPCR and for predicting the structures of other more
distant GPCRs. As additional GPCRs are crystallized to more
fully cover both sequence space and function space (through G
protein or β arrestin coupled pathways), such de novo prediction
methods should increase in accuracy because of additional
templates to initiate the process. Our results indicate that starting
with a template for a crystal for one subtype of a GPCR, we can
obtain accurate structures for the other subtypes. Also given a
crystal structure of one GPCR, we can obtain accurate structures
for other GPCRs that are within∼30% sequence identify for the
TM regions.
Figure 6. Predicted best models of the H3 selective antagonist clobenpropit 8 bound to hH1HR, hH2HR, hH3HR, hH4HR and other antagonists,
ciproxifan 9, thioperamide 10, A-304121 11, and A-317920 12 at hH3HR. H-bonding is indicated by red dots, and subtype selective residues are shown
in red.
Figure 7. Predicted binding energies (kcal/mol) to the H3 selective
antagonist clobenpropit 8 bound to hH1HR, hH2HR, hH3HR, hH4HR
and other antagonists, ciproxifan 9, thioperamide 10, A-304121 11, and
A-317920 12 at hH3HR listed in Table 5 compared with the experimental
binding constants (pKi). The dotted line shows the fit without two
outliers, 11 and 12, which is much more flexible than the others.
3271 dx.doi.org/10.1021/ci200435b |J. Chem. Inf. Model. 2011, 51, 3262–3274
Journal of Chemical Information and Modeling ARTICLE
’CONCLUSIONS
We docked several H3 selective ligands to all four subtypes to
determine the critical components defining H3 subtype selectivity
with respect to the other three subtypes obtained. Our predictions of
the best conformations of the histamine at H1, H2, H3, and H4
receptors subtypes lead to several conclusions: (1) The largest
contribution to binding of the H3 selective agonists (5, 6, 7) is
E2065.46 in good agreement with the experimental mutational
studies; (2) We find that the conserved E5.46/S5.43 in both of
hH3HR and hH4HR are involved in H3/ H4 subtype selectivity
through additional H-bonding with the terminal imidazole group in
the monoalkyl-substituted imidazole-based derivatives but loss of
these interactions in hH1HR and hH2HR. In addition, M378
6.55 in
hH3HR is another subtype selective residue provides additional
hydrophobic stabilization different from hH4HR (the corresponding
amino acid of T3236.55 in hH4HR); (3) Our proposed pharmaco-
phore model suggests that the residues important for selectivity to
hH3HR are: the basic proton interacting with D114
3.32, the spacer,
the aromatic ring substituted with the hydrophilic or lipophilic
groups interacting with lipophilic pockets in TMs 356, and the
aliphatic ring located in TMs 237.
We expect our predicted 3D structures for all four HRs will
help guide the rational design of novel H3 subtype selective
antagonists and agonists with reduced side effects. The excellent
agreement with current experimental studies, particularly the
understanding of H3 subtype selectivity indicates that computa-
tionally derived structures of GPCRs can be sufficiently accurate
to develop subtype selective drug to minimize side effects.
’METHODS
We used the GEnSeMBLE method2 to predict the 3D struc-
tures for the various conformations needed to understand the
function of GPCRs and help design new ligands. GEnSeMBLE
provides a very complete sampling (millions to quadrillions)
over possible rotations and tilts, leading to a ensemble of low-
lying structures expected to include those conformations en-
ergetically accessible for binding of ligands. This replaces our
earlier MembStruk method.31
We use the DarwinDock to predict the binding sites of ligands
to the GPCRs. DarwinDock samples ∼20 conformations for
∼50 000 poses expanding the predicted binding sites, which we
consider to be a very complete sampling. DarwinDock replaces
our earlier HierDock6 and MSCDock32 methods, providing a
much more complete sampling of possible poses. These earlier
methods were validated by a series of applications to various
GPCRs: human D2 dopamine receptor (DR),
33 human β2
adrenergic receptor,34,35 human M1 muscarinic receptor,
36 hu-
man Chemokine (CC) motif receptor 1 (CCR1),37 mouse
MrgC11 (mas related gene) for the molluscan peptide FMRF-
amide (FMRFa),38,39 human prostanoid DP receptor,40 human
Serotonin 2C,18 and human A2A adenosine
41 receptor.
GEnSeMBLE41. The structure prediction methodology has been
described previously41 so it will only be briefly summarized here:
(1) PredicTM: This uses multiple sequence alignment to
predict the TM regions for membrane protein.
(2) OptHelix/Homologize: OptHelix generate helices with
proper kinks (may be caused by Prolines) using molec-
ular dynamics. However when closely related X-ray
structures are available (as for the HRs), we find that
homology helices often provide better helix shapes.
(3) BiHelix: This algorithm samples all N7 packings of the 7
helices in a GPCR in which N rotations about each helix
are combine. Here we consider N = 13, which leads to
∼63 million conformations. BiHelix partitions the 7-helix
interaction problem into 12 sets of BiHelix interactions,
in which SCREAM17 is used to optimize the side chains
for each combination.
(4) CombiHelix: BiHelix energies for all 63 million packings
are used to select the best 1000. Then we build the full
Figure 8. Predicted binding sites of structurally known hH3HR in clinical study, ABT-239 1, GSK-189,254 2, and PF-3654746 3, and BF2.649
(tiprolisant) 4 at hHH3R. H-bonding is indicated by red dots.
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helix bundle for each of these 1000 and optimize the side
chains for each using SCREAM. From this 1000, we
select an ensemble of∼10 lowest energy structures, each
of which is used in docking of various ligands.
The Dreiding D3 force field (D3FF)42 was used throughout,
wherever energies were evaluated.
Ligand Docking. DarwinDock was used to dock several
ligands to each of the lowest 10 predicted structures of all
4 hHRs from BiHelix. The starting structure and charges of the
ligands in Chart 1 were calculated using density functional theory
(B3LYP with the 6-311G** basis set).
Starting from the X-ray structure of histamine, we rotated the
torsion angles NCalCalCar by 60 increments to generate 6
conformations. These were generated with the Maestro software
and minimized with the D3FF. The final docked structure with
the best binding E from all ligand conformations was selected.
Scanning the Receptor for Potential Binding Regions. Start-
ing with the predicted structure, we predicted putative ligands
binding regions as follows: We first alanized the entire protein
(replacing the 6 hydrophobic residues, I, L, V, F, Y, and W
with A) and scanned for potential binding regions with no
assumption about the binding site. The entire molecular surface
of the predicted structure was mapped with spheres representing
the empty volume of the protein (currently using the Sphgen
procedure in DOCK4.0 suite of programs). The entire set of
protein spheres was partitioned into∼3050 overlapping cubes
of 1014 Å sides. We then generated 1000 poses for each of
these 3050 regions. These results are compared to select the
most promising two or three putative binding regions.
DarwinDock. For each ligand conformation, we used Darwin-
Dock to generate iteratively∼50 000 poses spanning the putative
binding regions of the bulky residue-alanized protein. These poses
are partitioned into ∼1200 to ∼200 family head Voronai-like
families based on RMSD, and then calculated the energies of the
family heads and selected the top 10% ordered by total energy.
Next we calculated the binding energy for all the family
members of these top 10% family and selected the lowest
energy 100 structures for further optimization. For each of these
100, we dealanize the protein side chains (using SCREAM)
to find the optimum side chains for each of the best 100 poses.
Then we neutralize the protein and the ligand by transferring
protons appropriately within salt bridges and protonating or
deprotonating exterior ligands, followed by further full geometry
minimization.
DarwinDock has been validated for a number of X-ray
cocrystals including 3 crystal structures of ligand/GPCR com-
plexes: human β2-adrenergic receptor (0.4 Å RMSD),
15 human
AA2AR (0.8 Å RMSD),
43 and turkey β1-adrenergic receptor
(0.1 Å RMSD).16 This shows that DarwinDock can accurately
identify ligand binding sites in proteins, which can then be used
to optimize the ligands with desirable properties.
Neutralization for Scoring E. Quantum mechanics (QM)
calculations show that for an effective dielectric constant below
8, the extra proton on a Lys or Arg transfers back to the negative
carboxylate of an Asp or Glu. Thus we expect that buried salt
bridges will have neutral residues. We find that use of these
neutral residue charges for the protein and the ligand improves
the accuracy for comparing different docked structures. Of
course the final bond energy relative to ligand in the solvent
and binding site exposed to solvent must be corrected by
the effective pKA of the ligand and of the exposed Lys, Arg,
Glu, and Asp. For example, if the pKA of a carboxylate is 4.5 and
the solvent is taken to have a pH of 7.4, we must correct by
2.9  1.38 kcal/mol.
For external residues not involved in binding, we also find it is
expected to neutralize the external residues exposed to solvent or
membrane. Here the issue is that the force fields commonly used
in molecular dynamic calculations involve fixed charges, usually
Table 6. RMSD Matrix between Predicted Histamine
Receptors (top1 from BiHelix in Table 1) and the Recently
Reported3.1ÅCrystal Structureof thehH1HR(PDBID:3RZE)
11
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based on QM. In reality any net partial charges are shielded by
the dielectric polarization of the surrounding protein and solvent,
so that there is negligible effect beyond 10 Å. However with fixed
charges, the electrostatic interaction energy between two point
charges separated by 10 Å is 33 kcal/mol. The result is that small
changes in geometries of charged ligands far from the binding site
can lead to large differential binding energies, even 1030 kcal/
mol. We find that neutralizing these exposed residues removes
the sensitivity to details of the distances of charged residues (and
counterions) remote from the active site. This neutralization leads
to differential binding energies that are dominated by the local cavity
interactions and leads to much smaller solvation energies.18
’ASSOCIATED CONTENT
bS Supporting Information. Sequence identities of four
human HRs and X-ray structures, tβ1AR, hβ2AR, hAA2AR,
and bovine rhodopsin (Table S1); overview of residue number-
ing for the TM regions in each of the four HRs based
on homology to tβ1AR and human β2 adrenergic receptor
(Table S2). This information is available free of charge via the
Internet at http://pubs.acs.org.
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